Novonesis (Novozymes) B (OCSE:NSIS B) Other Long-Term Liabilities : kr10,348 Mil (As of Mar. 2025)

View and export this data going back to 2000. Start your Free Trial

What is Novonesis (Novozymes) B Other Long-Term Liabilities?

Novonesis (Novozymes) B's other long-term liabilities for the quarter that ended in Mar. 2025 was kr10,348 Mil.

Novonesis (Novozymes) B's quarterly other long-term liabilities increased from Jun. 2024 (kr11,524 Mil) to Dec. 2024 (kr21,861 Mil) but then declined from Dec. 2024 (kr21,861 Mil) to Mar. 2025 (kr10,348 Mil).

Novonesis (Novozymes) B's annual other long-term liabilities increased from Dec. 2022 (kr2,881 Mil) to Dec. 2023 (kr6,791 Mil) and increased from Dec. 2023 (kr6,791 Mil) to Dec. 2024 (kr21,861 Mil).

Novonesis (Novozymes) B Other Long-Term Liabilities Historical Data

The historical data trend for Novonesis (Novozymes) B's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novonesis (Novozymes) B Other Long-Term Liabilities Chart

Novonesis (Novozymes) B Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Long-Term Liabilities

Get a 7-Day Free Trial

1,474.65

2,850.58

2,880.59

6,790.83

21,860.75

Novonesis (Novozymes) B Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Dec24	Mar25
Other Long-Term Liabilities	Get a 7-Day Free Trial															6,790.83	-	11,524.40	21,860.75	10,348.20

Novonesis (Novozymes) B Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Novonesis (Novozymes) B Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Novonesis (Novozymes) B's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Novonesis (Novozymes) B Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Novonesis (Novozymes) B (OCSE:NSIS B) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

NVZMY:USA NVZMF:USA NSISBc:UK 0Q4U:UK NZM:Germany NZM:Germany NZM2:Germany NZM2:Germany NZYM:Austria

Address

Krogshoejvej 36, Bagsvaerd, DNK, 2880

Website

https://www.novozymes.com

Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.

Novonesis (Novozymes) B Headlines

No Headlines